BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blöchlinger S, Heg D, Jüni P, Windecker S. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv 2015;8:e002223. [PMID: 25858975 DOI: 10.1161/CIRCINTERVENTIONS.114.002223] [Cited by in Crossref: 44] [Cited by in F6Publishing: 13] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Canfield J, Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. J Pers Med 2018;8:E33. [PMID: 30275411 DOI: 10.3390/jpm8040033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
2 Trimukhe R, Vani P, Patel A, Salgotra V. Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario. World J Cardiol 2020;12:615-25. [PMID: 33391614 DOI: 10.4330/wjc.v12.i12.615] [Reference Citation Analysis]
3 Ray A, Najmi A, Khandelwal G, Jhaj R, Sadasivam B. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. Cardiovasc Drugs Ther 2021;35:561-74. [PMID: 32816142 DOI: 10.1007/s10557-020-07056-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zbinden R, Piccolo R, Heg D, Roffi M, Kurz DJ, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Franzone A, Eberli F, Jüni P, Windecker S, Pilgrim T. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. J Am Heart Assoc 2016;5:e003255. [PMID: 26979080 DOI: 10.1161/JAHA.116.003255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
5 Ortega-Gutierrez S, Lopez GV, Edgell RC, Mendez AA, Dandapat S, Roa JA, Zevallos CB, Holcombe AL, Hasan D, Derdeyn CP, Rossen J, Samaniego EA. Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience. Front Neurol 2019;10:746. [PMID: 31379708 DOI: 10.3389/fneur.2019.00746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Chisari A, Pistritto AM, Piccolo R, La Manna A, Danzi GB. The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence. Int J Mol Sci 2016;17:E1490. [PMID: 27608017 DOI: 10.3390/ijms17091490] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
7 Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circ Cardiovasc Interv 2016;9:e004256. [PMID: 27803041 DOI: 10.1161/CIRCINTERVENTIONS.116.004256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hamshere S, Byrne A, Choudhury T, Gallagher SM, Rathod KS, Lungley J, Knight CJ, Kapur A, Jones DA, Mathur A. Randomised trial of the comparison of drug-eluting stents in patients with diabetes: OCT DES trial. Open Heart 2018;5:e000705. [PMID: 29632674 DOI: 10.1136/openhrt-2017-000705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Panoulas VF, Mastoris I, Konstantinou K, Tespili M, Ielasi A. Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes. Med Devices (Auckl) 2015;8:317-29. [PMID: 26244031 DOI: 10.2147/MDER.S66360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Ki YJ, Park KW, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. J Interv Cardiol 2020;2020:3872704. [PMID: 32180687 DOI: 10.1155/2020/3872704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.118.007023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
12 Richelsen RK, Overvad TF, Jensen SE. Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review. Cardiol Ther 2016;5:133-60. [PMID: 27384194 DOI: 10.1007/s40119-016-0064-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
13 Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol 2017;9:640-51. [PMID: 28932353 DOI: 10.4330/wjc.v9.i8.640] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]